Advance Therapy Revenue and Competitors
Estimated Revenue & Valuation
- Advance Therapy's estimated annual revenue is currently $14.8M per year.
- Advance Therapy's estimated revenue per employee is $243,000
Employee Data
- Advance Therapy has 61 Employees.
- Advance Therapy grew their employee count by 13% last year.
Advance Therapy Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $350M | 926 | 15% | N/A | N/A |
#2 | $4.9M | 26 | -4% | N/A | N/A |
#3 | $17M | 70 | -22% | N/A | N/A |
#4 | $34.6M | 128 | 21% | N/A | N/A |
#5 | $24M | 89 | -20% | N/A | N/A |
#6 | $88.8M | 299 | 6% | N/A | N/A |
#7 | $122.9M | 364 | 14% | N/A | N/A |
#8 | $16.5M | 68 | 24% | N/A | N/A |
#9 | $663.3M | 1718 | 18% | $1.1B | N/A |
#10 | $1690M | 793 | 34% | N/A | N/A |
What Is Advance Therapy?
Advance Therapy is a hospital & health care company based out of 1415 E Colorado St # 212, Glendale, California, United States.
keywords:N/AN/A
Total Funding
61
Number of Employees
$14.8M
Revenue (est)
13%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Advance Therapy News
2022-04-20 - Coeptis Combines with Bull Horn in SPAC Deal to Advance ...
CD38-GEAR-NK is a natural killer (NK) cell- based therapy candidate that supports combination treatment with anti-CD38 monoclonal antibodies (...
2022-04-19 - Novel CAR T Therapy for Solid Tumors: 'Exciting Advance'
Now, a new CAR T construct that targets the tumor-specific antigen claudin 6 (CLDN6) is showing promising preliminary activity against relapsed...
2022-04-13 - Cell therapy biotech raises $120M to advance therapy to treat common cornea
condition
Aurion Biotech has raised $120 million to advance its cell therapy for an eye disorder that affects millions of people.
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $11.3M | 61 | 7% | N/A |
#2 | $18.1M | 61 | 0% | N/A |
#3 | $12.3M | 62 | -3% | N/A |
#4 | $15.1M | 62 | 15% | N/A |
#5 | $3.5M | 63 | 9% | N/A |